34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publication
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproli...
Citation: Experimental Hematology & Oncology 2013 2:2